Factors associated with treatment responses to pioglitazone in patients with steatotic liver disease: A 3-year prospective cohort study.

doi:10.1111/dom.15622

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Factors associated with treatment responses to pioglitazone in patients with steatotic liver disease: A 3-year prospective cohort study.

Diabetes, obesity & metabolism - 1 Jul 2024

Chang Ming-Ling, Tai Jennifer, Cheng Jur-Shan, Chen Wei-Ting, Yang Sien-Sing, Chiu Cheng-Hsun, Chien Rong-Nan

Abstract excerpt

AIM: The response rate to pioglitazone and the predictive factors for its effects on improving liver biochemistry in patients with steatotic liver disease (SLD) remain elusive, so we aimed to investigate these issues. METHODS: A 3-year prospective cohort study of 126 Taiwanese patients with SLD treated with pioglitazone (15-30 mg/day) was conducted. Phospholipase domain-containing protein 3 I148M rs738409,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aldehyde Dehydrogenase, Mitochondrial

Share to Fatty Liver

Share to Hypoglycemic Agents

Share to Lipoprotein Lipase

Share to Pioglitazone

Share to Taiwan

Share to Thiazolidinediones

Source

Open in PubMed

Identifiers

PMID: 38685616
DOI: 10.1111/dom.15622

Genes

ALDH2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Factors associated with treatment responses to pioglitazone in patients with steatotic liver disease: A 3-year prospective cohort study.PMID 38685616Read ↗

Efficacy and Safety of GLP-1 Receptor Agonists in Patients with MASLD: A Systematic Review and Meta-analysis of Randomized Clinical TrialsSemantic proximity Read ↗

Association of liver fibrosis with extrahepatic cancer in steatotic liver disease patients with PNPLA3 I148M GG genotype.Semantic proximity Read ↗

Genetic Factors Associated with Response to Vitamin E Treatment in NAFLDSemantic proximity Read ↗

Interplay of Mediterranean-diet adherence, genetic factors, and metabolic dysfunction-associated steatotic liver disease risk in Korea.Semantic proximity Read ↗

Analysis of PNPLA3, TM6SF2 and GCKR gene polymorphisms in patients with metabolic dysfunction-associated steatohepatitis treated with probiotics ‒ An exploratory study.Semantic proximity Read ↗

Antioxidant diet and genotyping as tools for the prevention of liver disease.Semantic proximity Read ↗

Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs.Semantic proximity Read ↗

Association of Antihypertensive Medication and Steatotic Liver Disease with Liver Fibrosis and Mortality among US AdultsSemantic proximity Read ↗

Genetic contribution to lipid target achievement with statin therapy: a prospective study.Semantic proximity Read ↗

ASSOCIATION ANALYSIS OF PIOGLITAZONE EFFECTIVENESS IN TREATMENT OF NAFLD PATIENTS WITH OBESITY AND PPARG RS1801282 (PRO12ALA) GENOTYPE.Semantic proximity Read ↗

Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment.Semantic proximity Read ↗

Evaluating the efficacy of GIPR agonists on non-alcoholic fatty liver disease: A Mediation Mendelian Randomization Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.